Clinical Trials Browser

Phase 2 × Trastuzumab × Tumor-Agnostic × Clear all

NCT00781612 2025-12-24

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

Phase 2 Active not recruiting

Neoplasm Metastasis

NCT01771458 2025-11-24

SHIVA

Phase 2 Completed

Neoplasm Metastasis

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

Neoplasms

NCT04551521 2025-01-08

CRAFT: The NCT-PMO-1602 Phase II Trial

Phase 2 Completed

Neoplasm Metastasis

NCT04309578 2024-02-28

A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC

Phase 2 Unknown

Adenocarcinoma

NCT03239015 2022-03-04

Efficacy and Safety of Precision Therapy in Refractory Tumor

Phase 2 Unknown

Neoplasms

NCT02213289 2021-04-08

PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

Phase 2 Completed

80 enrolled 14 charts

Adenocarcinoma

NCT01396707 2020-01-07

Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOX

Phase 2 Completed

Neoplasm Metastasis

NCT02142036 2019-03-13

MetAction

Phase 2 Completed

Neoplasm Metastasis

NCT03588533 2018-07-17

HERZUMA-GC

Phase 2 Unknown

Neoplasm Metastasis

NCT01472029 2017-06-19

HerFLOT

Phase 2 Completed

Adenocarcinoma